These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7083909)

  • 41. [Clofazimine and the eye].
    Negrel AD; Baquillon G; de La Panouse A; Ducam M; Bagadec R; Chovet M
    Acta Leprol; 1981; (84):31-7. PubMed ID: 6797221
    [No Abstract]   [Full Text] [Related]  

  • 42. The antileprotic action of clofazimine (B663, G30, 320, Lamprene).
    Azulay RD; da Silva NC; Zeo A; Portela AB; Franca JC; Peluso LL
    Int J Lepr Other Mycobact Dis; 1974; 42(1):13-8. PubMed ID: 4607163
    [No Abstract]   [Full Text] [Related]  

  • 43. [Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy].
    Rodríguez G; Pinto R; López F; Gómez Y
    Biomedica; 2009 Mar; 29(1):18-24. PubMed ID: 19753835
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clofazimine induced enteropathy--a case highlighting the importance of drug induced disease in differential diagnosis.
    Mathew BS; Pulimood AB; Prasanna CG; Ramakrishna BS; Chandy SJ
    Trop Gastroenterol; 2006; 27(2):87-8. PubMed ID: 17089619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study of toxicity of clofazimine with special reference to structural and functional status of small intestine.
    Kumar B; Bahadur B; Broor SL; Kaur S; Gangwar DN; Malik AK
    Lepr India; 1982 Apr; 54(2):246-55. PubMed ID: 7132294
    [No Abstract]   [Full Text] [Related]  

  • 46. Clofazimine and eosinophilic enteritis.
    Mason GH; Ellis-Pegler RB; Arthur JF
    Lepr Rev; 1977 Sep; 48(3):175-80. PubMed ID: 904424
    [No Abstract]   [Full Text] [Related]  

  • 47. [An unusual cause of parietal intestinal involvement: enteropathy due to clofazimine. Apropos of a case].
    Hassan M; Chaumet S; Brauner M; Labadie H
    Ann Radiol (Paris); 1986; 29(6):549-52. PubMed ID: 3800268
    [No Abstract]   [Full Text] [Related]  

  • 48. Multi-drug therapy in bacilliferous leprosy--two years experience.
    Kaur S; Sharma VK; Kumar B; Singh M; Kaur I
    Indian J Lepr; 1985; 57(3):483-90. PubMed ID: 3831085
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy trial with a triple-drug regimen, including once-monthly Rimactane (Rifampicin), in patients with multibacillary types of leprosy.
    Reyes-Javier PD; Tantiongco PR
    Acta Leprol; 1983; 1(3):133-41. PubMed ID: 6359801
    [No Abstract]   [Full Text] [Related]  

  • 50. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clofazimine induced nail changes.
    Dixit VB; Chaudhary SD; Jain VK
    Indian J Lepr; 1989 Oct; 61(4):476-8. PubMed ID: 2621382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
    Lockwood DN; Cunha Mda G
    Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient cream.
    Tadini G; Giustini S; Milani M
    Curr Med Res Opin; 2011 Dec; 27(12):2279-84. PubMed ID: 22007909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clofazimine induced pigmentation in leprosy patches.
    Chavhan SD; Jawade S
    Pan Afr Med J; 2022; 42():14. PubMed ID: 35812254
    [No Abstract]   [Full Text] [Related]  

  • 55. Long-term clinical toxicity studies with clofazimine (B663) in leprosy.
    Hastings RC; Jacobson RR; Trautman JR
    Int J Lepr Other Mycobact Dis; 1976; 44(3):287-93. PubMed ID: 824210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Small intestine transit anomalies in a patient with chronic abdominal pain and treated for Hansen's disease].
    Davy C; Riveau E; Bousquet JC; Curet P; Vayre P; Cortez A; Grellet J
    J Radiol; 1986 Mar; 67(3):213-8. PubMed ID: 3528476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clofazimine in pregnancy complicated by leprosy.
    Farb H; West DP; Pedvis-Leftick A
    Obstet Gynecol; 1982 Jan; 59(1):122-3. PubMed ID: 7078842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experience with multidrug therapy in paucibacillary leprosy.
    Bhate RD; Gupta CM; Chattopadhyay SP; Singh IP
    Indian J Lepr; 1986; 58(2):244-50. PubMed ID: 3805797
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug interactions -- the influence of rifampicin and clofazimine on the urinary excretion of DDS.
    Balakrishnan ; Seshadri PS
    Lepr India; 1981 Jan; 53(1):17-22. PubMed ID: 7218762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Experience with the combination of clofazimine (Lamprene) and long-term steroid therapy in the treatment of leprosy.
    Hogerzeil LM
    Lepr India; 1976 Oct; 48(4 Suppl):718-21. PubMed ID: 1026809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.